NCT03666715View on ClinicalTrials.gov

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

CompletedOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Schizophrenia
Interventions
DRUG

Oral Antipsychotics (OAPs)

No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.

DRUG

Paliperidone Palmitate 1-Month Formulation (PP1M)

No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.

Trial Locations (1)

4200 - 117

Neurobios , Instituto De Neurociências, Porto

All Listed Sponsors
lead

Janssen-Cilag Farmaceutica Ltda.

INDUSTRY

NCT03666715 - A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal | Biotech Hunter | Biotech Hunter